Results 101 to 110 of about 34,415 (160)

Immunosenescence and Vaccine Efficacy in Aging: Dynamic Interplay of Gut Microbiota and mTOR Signaling Pathways

open access: yesAging Cell, Volume 25, Issue 6, June 2026.
Aging impairs vaccine efficacy through gut microbiota dysbiosis and mTOR hyperactivation, which together drive inflammaging and weaken immune memory. This review highlights the bidirectional microbiota–mTOR axis and proposes that combining mTOR inhibitors with microbiota modulation offers a promising strategy to enhance vaccine responses in older ...
Jiaxuan Li   +5 more
wiley   +1 more source

Downstream Treatment Burden and Health‐Care Utilization Following Initiation of GLP‐1 Receptor Agonists or SGLT2 Inhibitors in Type 2 Diabetes

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 5163-5173, June 2026.
ABSTRACT Aims Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and sodium–glucose cotransporter 2 (SGLT2) inhibitors are widely used for the treatment of type 2 diabetes, yet their downstream consequences in routine clinical practice remain incompletely characterized.
Yazan Alhamdan   +2 more
wiley   +1 more source

Maternal Preconception Antibiotic Exposure Disrupts Microbial Succession: A Transgenerational Risk for Offspring Gut Mucosal Immaturity and Colitis Susceptibility

open access: yesAdvanced Science, Volume 13, Issue 29, 22 May 2026.
This study reveals that maternal antibiotic exposure prior to conception disrupts intergenerational gut microbial succession. By enhancing maternal‐offspring microbial transmission, altering microbial developmental trajectories and increasing selective pressures during community assembly, these disturbances lead to persistent gut mucosal immaturity and
Yuzhu Chen   +8 more
wiley   +1 more source

Gut Dysbiosis as a Shared Mechanism in Obesity and Hypertension: Exploring a Promising Therapeutic Avenue

open access: yesEndocrinology, Diabetes &Metabolism, Volume 9, Issue 3, May 2026.
This review synthesises current knowledge on gut microbiome involvement in obesity and hypertension, evaluates microbiome‐based therapeutic strategies, and identifies critical research gaps to guide future investigations aimed at mitigating the dual pandemics.
Andrej Belančić   +7 more
wiley   +1 more source

Natural Products as the Modulators of Gut Microbiota: A Pool for the Development of New Treatment Against Obesity?

open access: yesFood Frontiers, Volume 7, Issue 3, May 2026.
Natural compounds regulate gut microbiota by improving microbial balance and increasing probiotics, which boost short‐chain fatty acid production to alleviate insulin resistance and inflammation. Additionally, they stimulate appetite‐suppressing hormones through bile acid signaling, while inhibiting pathogenic bacteria to repair intestinal barrier ...
Hongchao Yuan   +7 more
wiley   +1 more source

Inactivation Strategies of Clostridium perfringens in Foods: Current Challenges and Emerging Interventions

open access: yesFood Frontiers, Volume 7, Issue 3, May 2026.
Clostridium perfringens forms heat‐resistant spores that complicate food safety. Physical methods (thermal processing, HPP, vacuum cooling, ozone treatments) and chemical interventions (natural antimicrobials, phosphates, nitrate/nitrite, organic acids) reduce vegetative cells and spores, though spore resistance remains a major challenge in food and ...
Deepak Subedi   +7 more
wiley   +1 more source

Probiotics Cancer Interaction, Prevention, and Therapy

open access: yesImmunity, Inflammation and Disease, Volume 14, Issue 5, May 2026.
ABSTRACT Cancer is a significant global health concern and ranks as the second most common cause of death on a worldwide scale. A combination of hereditary and lifestyle variables, such as diet, smoking, alcohol consumption, physical exercise, and the gut microbiota, impacts cancer development. Dysbiosis, an imbalance in gut microorganisms, can promote
Mostafa Saebi   +7 more
wiley   +1 more source

Perceptions of fecal microbiota transplantation for Clostridium difficile infection: factors that predict acceptance. [PDF]

open access: yes, 2016
BackgroundDespite the effectiveness of fecal microbiota transplantation (FMT) for treating recurrent Clostridium difficile (C. difficile) infection, some patients are reluctant to accept this therapy.
Chen, Lea Ann   +7 more
core   +1 more source

LL‐37: Biological Mechanisms and Emerging Therapeutic Applications in Intestinal Disease

open access: yesImmunity, Inflammation and Disease, Volume 14, Issue 5, May 2026.
ABSTRACT Human cathelicidin peptide LL‐37 is encoded by the CAMP gene and plays a key role in innate immunity. It maintains intestinal homeostasis through antibacterial, immunomodulation, and tissue repair functions. This paper reviews the multiple functions of LL‐37 in the intestinal‐immune axis and its contribution to intestinal immune homeostasis. A
Qichao Liu, Peng Xu, Cheng Zhang
wiley   +1 more source

Probiotic‐based strategies in vulvovaginal candidiasis management: A comprehensive review of mechanisms and future directions

open access: yesInterdisciplinary Medicine, Volume 4, Issue 3, May 2026.
This review focuses on vulvovaginal candidiasis (VVC), examining its epidemiology, the pathogenesis of Candida albicans, and its relationships with vaginal microbiota. It comprehensively reviews probiotic‐based management strategies and their mechanisms of action, and concludes by discussing current limitations, challenges and future research ...
Tong Chen   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy